2015
DOI: 10.1200/jco.2015.61.6490 View full text |Buy / Rent full text
|
|

Abstract: Purpose Progesterone receptors are expressed in approximately 70% of meningiomas. Mifepristone is an oral antiprogestational agent reported to have modest activity in a phase II study. This multicenter, prospective, randomized, placebo-controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the treatment of unresectable meningioma. Patients and Methods Eligible patients were randomly assigned to receive either mifepristone or placebo for 2 years unless disease progressed.… Show more

Help me understand this page

Search citation statements

Order By: Relevance
0
0
0
0
0
1
43
0

Publication Types

Select...

Relationship

0
0

Authors

Journals